114.31

1.65% -1.92

Corcept Therapeutics Inc (CORT)

Overview News Price History Option Chain Financials Discussions Forecast

Corcept Therapeutics Inc stock is traded at $114.31, with a volume of 307.29K. It is down -1.65% in the last 24 hours and up +3.15% over the past month. Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.

Previous Close:

$116.23

Open:

$116.31

24h Volume:

307.29K

Relative Volume:

0.43

Market Cap:

$12.36B

Revenue:

$769.10M

Net Income/Loss:

$46.67M

P/E Ratio:

326.60

EPS:

0.35

Net Cash Flow:

$119.79M

1W Performance:

-3.57%

1M Performance:

+3.15%

6M Performance:

+160.39%

1Y Performance:

+48.82%

1-Day Range:

$113.04

$117.48

1-Week Range:

$115.95

$122.81

52-Week Range:

$28.66

$126.38

Corcept Therapeutics Inc Stock (CORT) Company Profile

Name

Corcept Therapeutics Inc

Sector

Healthcare (1051)

Industry

Biotechnology (593)

Phone

650.688.8803

Address

101 REDWOOD SHORES PARKWAY, REDWOOD CITY

Employee

730

Twitter

Next Earnings Date

2026-11-03

Latest SEC Filings

CORT's Discussions on Twitter

Compare CORT vs VRTX, MRNA, REGN, ARGX, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CORT Corcept Therapeutics Inc	114.31	12.36B	769.10M	46.67M	119.79M	0.35
VRTX Vertex Pharmaceuticals Inc	510.13	129.30B	12.34B	4.34B	3.71B	16.87
MRNA Moderna Inc	237.70	94.90B	2.23B	-3.19B	-1.60B	-8.1462
REGN Regeneron Pharmaceuticals Inc	801.21	82.49B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	848.03	53.33B	4.16B	1.29B	734.26M	19.58
ONC Beone Medicines Ltd Adr	370.95	41.96B	5.76B	514.49M	1.10B	4.4813

Corcept Therapeutics Inc Stock (CORT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-18-26	Resumed	Truist	Buy
Jul-27-26	Downgrade	Wolfe Research	Peer Perform → Underperform
May-13-26	Upgrade	UBS	Neutral → Buy
Mar-26-26	Upgrade	Wolfe Research	Underperform → Peer Perform
Dec-31-25	Downgrade	Wolfe Research	Peer Perform → Underperform
Dec-16-25	Initiated	UBS	Neutral
Nov-18-25	Initiated	Wolfe Research	Peer Perform
Nov-06-23	Upgrade	Truist	Hold → Buy
Apr-11-23	Initiated	SVB Securities	Market Perform
Apr-04-23	Initiated	Piper Sandler	Overweight
Feb-15-23	Downgrade	Jefferies	Buy → Hold
Aug-01-22	Downgrade	Truist	Buy → Hold
Jul-27-22	Upgrade	Jefferies	Hold → Buy
Jun-27-22	Resumed	Canaccord Genuity	Buy
Feb-02-22	Initiated	Canaccord Genuity	Buy
Jan-28-22	Initiated	Truist	Buy
Aug-05-20	Downgrade	Jefferies	Buy → Hold
Sep-24-19	Initiated	Jefferies	Buy
Sep-06-19	Initiated	H.C. Wainwright	Buy
Feb-04-19	Downgrade	B. Riley FBR	Buy → Neutral
Aug-10-18	Reiterated	Stifel	Hold
May-31-18	Downgrade	Stifel	Buy → Hold
Mar-09-18	Initiated	B. Riley FBR, Inc.	Buy
Aug-31-17	Initiated	Stifel	Buy
Feb-02-17	Initiated	Ladenburg Thalmann	Buy
Apr-21-15	Initiated	FBR Capital	Outperform
Jan-13-14	Downgrade	Stifel	Buy → Hold
Aug-09-13	Downgrade	Janney	Buy → Neutral
Aug-09-13	Downgrade	Ladenburg Thalmann	Buy → Neutral
Feb-21-12	Reiterated	JMP Securities	Mkt Outperform
Jan-06-10	Upgrade	Ladenburg Thalmann	Neutral → Buy
Jul-17-08	Initiated	Rodman & Renshaw	Mkt Outperform
Jun-21-07	Upgrade	Punk, Ziegel & Co	Mkt Perform → Accumulate

View All

Corcept Therapeutics Inc Stock (CORT) Latest News

Oct 14, 2026

LQDA Settles UTHR Disputes for $380.7M, Limits Yutrepia Label - Zacks Investment Research

Oct 14, 2026

Here's Why You Should Add ANRO Stock to Your Portfolio Now - Zacks Investment Research

Oct 14, 2026

Syndax Stock Falls 16% as Phase II Fibrosis Study Misses Primary Goal - Zacks Investment Research

Oct 14, 2026

Oct 13, 2026

BMY Reports Mixed Phase III Trial Results, Stock Down - Zacks Investment Research

Oct 13, 2026

Are Options Traders Betting on a Big Move in Corcept Therapeutics Stock? - Zacks Investment Research

Oct 13, 2026

Oct 12, 2026

Drugmaker Corcept seeks to bar ex-judge's views in Teva antitrust case - Reuters

Oct 12, 2026

Prime Medicine Stock Rallies Nearly 26% in a Month: Here's Why - Zacks Investment Research

Oct 12, 2026

PMVP Stock Rises 19% in 3 Months: Here's What You Need to Know - Zacks Investment Research

Oct 12, 2026

Oct 10, 2026

Corcept Therapeutics Inc (HTD.DU) Stock Forum & Discussion - Yahoo! Finance Canada

Oct 10, 2026

Oct 09, 2026

Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Erasca, Inc. (ERAS), DICK’S Sporting Goods, Inc. (DKS), Corcept Therapeutics Incorporated (CORT), and Charter Communications, Inc. (CHTR) - Supply Chain Digital

Oct 09, 2026

Oct 08, 2026

Piper Sandler Keeps Their Buy Rating on Corcept Therapeutics (CORT) - The Globe and Mail

Oct 08, 2026

Corcept Therapeutics Incorporat (CORT) Stock Forecasts - Yahoo Finance

Oct 08, 2026

Oct 06, 2026

Corcept Therapeutics Insider Sold Shares Worth $2,906,601, According to a Recent SEC Filing - Yahoo Finance

Oct 06, 2026

Corcept Therapeutics (NasdaqCM:CORT) Stock Forecast & Analyst Predictions - Simply Wall Street

Oct 06, 2026

Oct 05, 2026

Form 4 Corcept Therapeutics Incorporated For: 5 October By Investing.com - Investing.com India

Oct 05, 2026

Form 4 Corcept Therapeutics Incorporated For: 5 October By Investing.com - Investing.com Nigeria

Oct 05, 2026

Corcept Therapeutics president Sean Maduck sells $2.9 million in stock By Investing.com - Investing.com Australia

Oct 05, 2026

Corcept Therapeutics president Sean Maduck sells $2.9 million in stock - Investing.com

Oct 05, 2026

Corcept Therapeutics president sells $967k in shares - Investing.com

Oct 05, 2026

Corcept Therapeutics chief accounting officer sells $1.16m - Investing.com

Oct 05, 2026

Corcept Therapeutics Oncology President Reports Stock Option Exercise and Sales in Form 4 Filing - Kalkine Media

Oct 05, 2026

Corcept Therapeutics' Sean Maduck Executes Stock Option Exercises and Sells Shares Under 10b5-1 Plan - Kalkine Media

Oct 05, 2026

100,000 stock options awarded to Corcept (CORT) officer vest over four years, subject to continued service. - Stock Titan

Oct 05, 2026

An officer reports 12,191 shares, including unvested awards, and four option positions at Corcept (CORT). - Stock Titan

Oct 05, 2026

The Zacks Analyst Blog Highlights Abbott, Corcept, Precigen and Bausch Health Companies - Zacks Investment Research

Oct 05, 2026

Corcept Therapeutics Incorporated (CORT) Stock Price, News, Quote & History - Yahoo! Finance Canada

Oct 05, 2026

The Zacks Analyst Blog Highlights Abbott, Corcept, Precigen and Bausch Health Companies - Yahoo Finance

Oct 05, 2026

Oct 02, 2026

Corcept Therapeutics Inc. R (HTD.DU) Q1 FY2026 earnings call transcript - Yahoo Finance

Oct 02, 2026

4 Low-Beta Healthcare Stocks to Buy Amid Fears of Another Rate Hike - Zacks Investment Research

Oct 02, 2026

Oct 01, 2026

After a $1.13M September sale, Corcept (CORT) officer proposes another share sale. - stocktitan.net

Oct 01, 2026

Sep 29, 2026

Non-controlling/minority interest of Corcept Therapeutics Incorporated. – HAN:HTD - TradingView

Sep 29, 2026

Sep 28, 2026

Corcept Therapeutics (CORT) business chief gifts shares; two custodial accounts acquire 5,000 each - stocktitan.net

Sep 28, 2026

Form 4 Corcept Therapeutics Incorporated For: 28 September By Investing.com - Investing.com Nigeria

Sep 28, 2026

Corcept Therapeutics’ oncology president sells $29,842 in stock - Investing.com

Sep 28, 2026

Form 4 Corcept Therapeutics Incorporated For: 28 September By Investing.com - Investing.com Canada

Sep 28, 2026

Sep 25, 2026